Clinical efficacy and safety of alteplase in the treatment of acute cerebral infarction
阿替普酶治疗急性脑梗死的临床疗效及安全性

摘要

目的 分析在急性脑梗死治疗中应用阿替普酶的治疗效果。方法 择定2021年5月-2023年5月研究时段内在本院就诊的罹患急性脑梗死患者72例作为试验进行对象，以治疗方式的区别、划分36例常规治疗（非溶栓）的患者为对照组，而36例接受了阿替普酶溶栓治疗的患者为观察组，对比两组治疗各个时段的NHISS脑神经缺损评分以及用药的不良反应。结果 两组治疗前，NHISS神经缺损评分无显著差异，P﹥0.05。而在治疗后的6h、24h以及72h患者NHISS评分有明显降低，差异显著P﹤0.05。而在不良反应的对比上，观察组发生症不良反应的人数相较对照组，数值较小，差异不显著，P﹥0.05，结论 阿替普酶可改善急性脑梗死患者的神经受损情况，降低预后康复障碍，同时用药反应较低，治疗安全性好。

Abstract

Objective To analyze the efficacy of alteplase in the treatment of acute cerebral infarction.
Methods seventy-two patients with acute cerebral infarction, who were treated in our hospital during the study period from May to 20232021, were selected for the study, according to the difference of treatment methods, 36 patients with conventional therapy (non-thrombolytic therapy) were divided into control group and 36 patients with thrombolytic therapy of alteplase were divided into observation group, the NHISS neurological deficit scale (NDS) and adverse drug reactions (adrs) were compared between the two groups.
Results before treatment, there was no significant difference in NHISS nerve defect score between the two groups (P > 0.05) . The NHISS scores of the patients were significantly decreased at 6H, 24h and 72h after treatment (p < 0.05) . On the side effects, the number of symptomatic cerebral hemorrhage, subcutaneous mucosal hemorrhage and oral hemorrhage in the observation group was significantly lower than that in the control group (p ﹥ 0.05) .
Conclusion   alteplase can improve the nerve damage of patients with acute cerebral infarction, reduce the prognosis of rehabilitation disorders, and the drug reaction is low, the treatment of safety is good.